NCT00429091

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose-Ranging Study of the Safety and Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 243 (actual)
• Sponsor: Abbott · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Conditions

• Attention-Deficit/Hyperactivity Disorder
• ADHD

Interventions

Type	Name	Description
DRUG	ABT-894	Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
DRUG	atomoxetine	Subjects will take 40 mg BID or placebo for up to four weeks.
DRUG	placebo	Subjects will take BID for up to four weeks

Timeline

• Start date: 2007-01-01
• Primary completion: 2007-08-01
• First posted: 2007-01-31
• Last updated: 2010-11-02

Locations

22 sites across 1 country: United States